-
1
-
-
33746707858
-
High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: Adjuvant or alternative to conventional modalities
-
Bruland OS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: Adjuvant or alternative to conventional modalities? Clin Cancer Res 2006; 12:6250s–6257s.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 6250s-6257s
-
-
Bruland, O.S.1
Nilsson, S.2
Fisher, D.R.3
Larsen, R.H.4
-
2
-
-
0036606104
-
Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model
-
Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res 2002; 62:3120–3125.
-
(2002)
Cancer Res
, vol.62
, pp. 3120-3125
-
-
Henriksen, G.1
Breistol, K.2
Bruland, O.S.3
Fodstad, O.4
Larsen, R.H.5
-
3
-
-
0037315930
-
Targeting of osseous sites with alpha-emitting 223Ra: Comparison with the beta-emitter 89Sr in mice
-
Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: Comparison with the beta-emitter 89Sr in mice. J Nucl Med 2003; 44:252–259.
-
(2003)
J Nucl Med
, vol.44
, pp. 252-259
-
-
Henriksen, G.1
Fisher, D.R.2
Roeske, J.C.3
Bruland, O.S.4
Larsen, R.H.5
-
4
-
-
84880428467
-
Alpha emitter radium-223 and survival in metastatic prostate cancer
-
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzen L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O, Investigators A. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369:213–223.
-
(2013)
N Engl J Med
, vol.369
, pp. 213-223
-
-
Parker, C.1
Nilsson, S.2
Heinrich, D.3
Helle, S.I.4
O'Sullivan, J.M.5
Fossa, S.D.6
Chodacki, A.7
Wiechno, P.8
Logue, J.9
Seke, M.10
Widmark, A.11
Johannessen, D.C.12
Hoskin, P.13
Bottomley, D.14
James, N.D.15
Solberg, A.16
Syndikus, I.17
Kliment, J.18
Wedel, S.19
Boehmer, S.20
Dall'Oglio, M.21
Franzen, L.22
Coleman, R.23
Vogelzang, N.J.24
O'Bryan-Tear, C.G.25
Staudacher, K.26
Garcia-Vargas, J.27
Shan, M.28
Bruland, O.S.29
Sartor, O.30
Investigators, A.31
more..
-
5
-
-
4744337716
-
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
-
Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513–1520.
-
(2004)
N Engl J Med
, vol.351
, pp. 1513-1520
-
-
Petrylak, D.P.1
Tangen, C.M.2
Hussain, M.H.3
Lara, P.N.4
Jones, J.A.5
Taplin, M.E.6
Burch, P.A.7
Berry, D.8
Moinpour, C.9
Kohli, M.10
Benson, M.C.11
Small, E.J.12
Raghavan, D.13
Crawford, E.D.14
-
6
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
Investigators TAX
-
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, Investigators TAX. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502–1512.
-
(2004)
N Engl J Med
, vol.351
, pp. 1502-1512
-
-
Tannock, I.F.1
de Wit, R.2
Berry, W.R.3
Horti, J.4
Pluzanska, A.5
Chi, K.N.6
Oudard, S.7
Theodore, C.8
James, N.D.9
Turesson, I.10
Rosenthal, M.A.11
Eisenberger, M.A.12
-
7
-
-
84875932058
-
Abiraterone in metastatic prostate cancer without previous chemotherapy
-
Ryan C, Smith M, de Bono J, Molina A, Logothetis C, de Souza P, Fizazi K, Mainwaring P, Piulats J, Siobhan N, Carles J, Mulders P, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee S, Suttmann H, Gerristen W, Flaig T, George D, Yu E, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:1458–1459.
-
(2013)
N Engl J Med
, vol.368
, pp. 1458-1459
-
-
Ryan, C.1
Smith, M.2
de Bono, J.3
Molina, A.4
Logothetis, C.5
de Souza, P.6
Fizazi, K.7
Mainwaring, P.8
Piulats, J.9
Siobhan, N.10
Carles, J.11
Mulders, P.12
Basch, E.13
Small, E.J.14
Saad, F.15
Schrijvers, D.16
Van Poppel, H.17
Mukherjee, S.18
Suttmann, H.19
Gerristen, W.20
Flaig, T.21
George, D.22
Yu, E.23
Efstathiou, E.24
Pantuck, A.25
Winquist, E.26
Higano, C.S.27
Taplin, M.E.28
Park, Y.29
Kheoh, T.30
Griffin, T.31
Scher, H.I.32
Rathkopf, D.E.33
more..
-
8
-
-
77955066199
-
Sipuleucel-T immunotherapy for castration-resistant prostate cancer
-
Investigators IS
-
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, Investigators IS. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411–422.
-
(2010)
N Engl J Med
, vol.363
, pp. 411-422
-
-
Kantoff, P.W.1
Higano, C.S.2
Shore, N.D.3
Berger, E.R.4
Small, E.J.5
Penson, D.F.6
Redfern, C.H.7
Ferrari, A.C.8
Dreicer, R.9
Sims, R.B.10
Xu, Y.11
Frohlich, M.W.12
Schellhammer, P.F.13
-
9
-
-
84904871070
-
Enzalutamide in metastatic prostate cancer before chemotherapy
-
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371:424–433.
-
(2014)
N Engl J Med
, vol.371
, pp. 424-433
-
-
Beer, T.M.1
Armstrong, A.J.2
Rathkopf, D.E.3
Loriot, Y.4
Sternberg, C.N.5
Higano, C.S.6
Iversen, P.7
Bhattacharya, S.8
Carles, J.9
Chowdhury, S.10
Davis, I.D.11
de Bono, J.S.12
Evans, C.P.13
Fizazi, K.14
Joshua, A.M.15
Kim, C.S.16
Kimura, G.17
Mainwaring, P.18
Mansbach, H.19
Miller, K.20
Noonberg, S.B.21
Perabo, F.22
Phung, D.23
Saad, F.24
Scher, H.I.25
Taplin, M.E.26
Venner, P.M.27
Tombal, B.28
more..
-
10
-
-
84866770294
-
Increased survival with enzalutamide in prostate cancer after chemotherapy
-
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187–1197.
-
(2012)
N Engl J Med
, vol.367
, pp. 1187-1197
-
-
Scher, H.I.1
Fizazi, K.2
Saad, F.3
Taplin, M.E.4
Sternberg, C.N.5
Miller, K.6
de Wit, R.7
Mulders, P.8
Chi, K.N.9
Shore, N.D.10
Armstrong, A.J.11
Flaig, T.W.12
Flechon, A.13
Mainwaring, P.14
Fleming, M.15
Hainsworth, J.D.16
Hirmand, M.17
Selby, B.18
Seely, L.19
de Bono, J.S.20
more..
-
11
-
-
84908594586
-
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
-
Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 2014; 15:1397–1406.
-
(2014)
Lancet Oncol
, vol.15
, pp. 1397-1406
-
-
Hoskin, P.1
Sartor, O.2
O'Sullivan, J.M.3
Johannessen, D.C.4
Helle, S.I.5
Logue, J.6
Bottomley, D.7
Nilsson, S.8
Vogelzang, N.J.9
Fang, F.10
Wahba, M.11
Aksnes, A.K.12
Parker, C.13
-
12
-
-
84973353075
-
Safety of radium-223 dichloride with docetaxel in patients with bone metastases from castration-resistant prostate cancer: A phase 1/2a clinical trial
-
Abstr 765PD
-
Morris MJ, Higano CS, Scher HI, Sweeney C, Antonarakis ES, Shevrin DH, Ryan C, Loriot Y, Fizazi K, Pandit-Taskar N, Garcia-Vargas J, Lyseng K, Bloma M, Aksnes AK, Carrasquillo J. Safety of radium-223 dichloride with docetaxel in patients with bone metastases from castration-resistant prostate cancer: A phase 1/2a clinical trial. Ann Oncol 2014; 25(Suppl 4):iv261. Abstr 765PD.
-
(2014)
Ann Oncol
, vol.25
, pp. iv261
-
-
Morris, M.J.1
Higano, C.S.2
Scher, H.I.3
Sweeney, C.4
Antonarakis, E.S.5
Shevrin, D.H.6
Ryan, C.7
Loriot, Y.8
Fizazi, K.9
Pandit-Taskar, N.10
Garcia-Vargas, J.11
Lyseng, K.12
Bloma, M.13
Aksnes, A.K.14
Carrasquillo, J.15
-
13
-
-
84865309361
-
Toxicity in patients receiving adjuvant docetaxel+hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: A preplanned safety report of the SPCG-13 trial
-
Kellokumpu-Lehtinen PL, Hjalm-Eriksson M, Thellenberg-Karlsson C, Astrom L, Franzen L, Marttila T, Seke M, Taalikka M, Ginman C. Toxicity in patients receiving adjuvant docetaxel+hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: A preplanned safety report of the SPCG-13 trial. Prostate Cancer Prostatic Dis 2012; 15:303–307.
-
(2012)
Prostate Cancer Prostatic Dis
, vol.15
, pp. 303-307
-
-
Kellokumpu-Lehtinen, P.L.1
Hjalm-Eriksson, M.2
Thellenberg-Karlsson, C.3
Astrom, L.4
Franzen, L.5
Marttila, T.6
Seke, M.7
Taalikka, M.8
Ginman, C.9
-
14
-
-
77954313173
-
Anemia in men with advanced prostate cancer: Incidence, etiology, and treatment
-
Nalesnik J, Mysliwiec A, Canby-Hagino E. Anemia in men with advanced prostate cancer: Incidence, etiology, and treatment. Rev Urol 2004; 6:1–4.
-
(2004)
Rev Urol
, vol.6
, pp. 1-4
-
-
Nalesnik, J.1
Mysliwiec, A.2
Canby-Hagino, E.3
-
15
-
-
77953311958
-
Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases
-
Nieder C, Haukland E, Pawinski A, Dalhaug A. Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases. BMC Cancer 2010; 10:284.
-
(2010)
BMC Cancer
, vol.10
, pp. 284
-
-
Nieder, C.1
Haukland, E.2
Pawinski, A.3
Dalhaug, A.4
-
16
-
-
84982310631
-
ERA223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients with bone predominant metastatic castration-resistant prostate cancer
-
Abstr TPS5082
-
Smith M, Parker C, Tombal B, Miller K, Saad F, Fang F, Zhang A, Kornacker M, Higano CS. ERA223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naive patients with bone predominant metastatic castration-resistant prostate cancer. J Clin Oncol 2015; 33: Abstr TPS5082.
-
(2015)
J Clin Oncol
, vol.33
-
-
Smith, M.1
Parker, C.2
Tombal, B.3
Miller, K.4
Saad, F.5
Fang, F.6
Zhang, A.7
Kornacker, M.8
Higano, C.S.9
|